Neuraxpharm Aims For Sales Of €400m By Year End

The Projected Total Represents Organic Growth Of 10%

After recently rebranding the company, Neuraxpharm has put expansion plans in place that have allowed it to reach over 70% of the European central nervous system market, resulting in projections of organic sales growth of 10% and gross sales of €400m for this year.

Euro_Sign
Neuraxpharm’s presence in Europe has grown to nine countries • Source: Shutterstock

Neuraxpharm Group is on track to achieve organic net sales growth of 10% in 2019, with expected gross sales of €400m ($436m) this year, the firm has disclosed in a business update.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By 

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By 

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By 

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.